Kaideni, a digital therapy enterprise for chronic kidney disease management, completed more than 100 million yuan of a + round financing

Beijing kaideni Medical Technology Co., Ltd. announced the completion of a + round of financing of more than 100 million yuan. Founded in 2015, kaideni medical is a management platform for the whole course of chronic kidney disease, focusing on the out of hospital scene of patients with kidney disease. It is led by well-known private investment institutions and jade capital, followed by Yidu technology, probe new medical fund, old shareholder Shunwei capital, Kaifeng venture capital and other leading enterprises of medical artificial intelligence. Probe capital acts as the exclusive financial adviser. The proceeds from this round of financing are mainly used to accelerate the clinical research of digital medical therapy for chronic diseases and the expansion of the company's follow-up team. Previously, kedney medical completed Angel round, pre-A round and a round of financing in 2015, 2017 and 2019 respectively. The investment institutions behind it include Shunwei capital, Kaifeng venture capital, Shangshi capital and Zehou capital. After several rounds of financing, the accumulated funds raised by kedney medical have reached hundreds of millions of yuan.